148 related articles for article (PubMed ID: 32753706)
1. The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG.
Dalle JH; Balduzzi A; Bader P; Pieczonka A; Yaniv I; Lankester A; Bierings M; Yesilipek A; Sedlacek P; Ifversen M; Svec P; Toporski J; Gungor T; Wachowiak J; Glogova E; Poetschger U; Peters C
Bone Marrow Transplant; 2021 Jan; 56(1):257-266. PubMed ID: 32753706
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on Outcomes.
Dalle JH; Balduzzi A; Bader P; Lankester A; Yaniv I; Wachowiak J; Pieczonka A; Bierings M; Yesilipek A; Sedlaçek P; Ifversen M; Sufliarska S; Toporski J; Glogova E; Poetschger U; Peters C
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1848-1855. PubMed ID: 29772352
[TBL] [Abstract][Full Text] [Related]
3. Transplantation in Children and Adolescents with Acute Lymphoblastic Leukemia from a Matched Donor versus an HLA-Identical Sibling: Is the Outcome Comparable? Results from the International BFM ALL SCT 2007 Study.
Balduzzi A; Dalle JH; Wachowiak J; Yaniv I; Yesilipek A; Sedlacek P; Bierings M; Ifversen M; Sufliarska S; Kalwak K; Lankester A; Toporski J; Di Maio L; Glogova E; Poetschger U; Peters C
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2197-2210. PubMed ID: 31319153
[TBL] [Abstract][Full Text] [Related]
4. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95.
Schrauder A; Reiter A; Gadner H; Niethammer D; Klingebiel T; Kremens B; Peters C; Ebell W; Zimmermann M; Niggli F; Ludwig WD; Riehm H; Welte K; Schrappe M
J Clin Oncol; 2006 Dec; 24(36):5742-9. PubMed ID: 17179108
[TBL] [Abstract][Full Text] [Related]
5. Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.
Santoro N; Ruggeri A; Labopin M; Bacigalupo A; Ciceri F; Gülbaş Z; Huang H; Afanasyev B; Arcese W; Wu D; Koc Y; Tischer J; Santarone S; Giebel S; Mohty M; Nagler A
J Hematol Oncol; 2017 May; 10(1):113. PubMed ID: 28558762
[TBL] [Abstract][Full Text] [Related]
6. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
[TBL] [Abstract][Full Text] [Related]
7. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
Rubio MT; Savani BN; Labopin M; Piemontese S; Polge E; Ciceri F; Bacigalupo A; Arcese W; Koc Y; Beelen D; Gülbas Z; Wu D; Santarone S; Tischer J; Afanasyev B; Schmid C; Giebel S; Mohty M; Nagler A
J Hematol Oncol; 2016 Mar; 9():25. PubMed ID: 26980295
[TBL] [Abstract][Full Text] [Related]
8. Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial.
Peters C; Schrappe M; von Stackelberg A; Schrauder A; Bader P; Ebell W; Lang P; Sykora KW; Schrum J; Kremens B; Ehlert K; Albert MH; Meisel R; Matthes-Martin S; Gungor T; Holter W; Strahm B; Gruhn B; Schulz A; Woessmann W; Poetschger U; Zimmermann M; Klingebiel T
J Clin Oncol; 2015 Apr; 33(11):1265-74. PubMed ID: 25753432
[TBL] [Abstract][Full Text] [Related]
9. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.
Kebriaei P; Bassett R; Lyons G; Valdez B; Ledesma C; Rondon G; Oran B; Ciurea S; Alousi A; Popat U; Patel K; Ahmed S; Olson A; Bashir Q; Shah N; Jones R; Marin D; Rezvani K; Nieto Y; Khouri I; Qazilbash M; Hosing C; Shpall E; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2017 Feb; 23(2):285-292. PubMed ID: 27816651
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study.
Sakellari I; Gavriilaki E; Chatziioannou K; Papathanasiou M; Mallouri D; Batsis I; Bousiou Z; Bouziana S; Constantinou V; Douka V; Apostolou C; Iskas M; Lalayanni C; Athanasiadou A; Sotiropoulos D; Yannaki E; Gianouzakos V; Anagnostopoulos A
Ann Hematol; 2018 Oct; 97(10):1987-1994. PubMed ID: 29869673
[TBL] [Abstract][Full Text] [Related]
11. [Allogeneic hematopoietic stem cell transplantation for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia].
Xu LP; Huang XJ; Liu KY; Chen H; Liu DH; Zhang YC; Chen YH; Han W; Gao ZY; Lu DP
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Jun; 37(3):231-5. PubMed ID: 15968308
[TBL] [Abstract][Full Text] [Related]
12. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
[TBL] [Abstract][Full Text] [Related]
13. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.
Rubio MT; Savani BN; Labopin M; Polge E; Niederwieser D; Ganser A; Schwerdtfeger R; Ehninger G; Finke J; Renate A; Craddock C; Kröger N; Hallek M; Jindra P; Mohty M; Nagler A
J Hematol Oncol; 2016 Aug; 9(1):65. PubMed ID: 27488518
[TBL] [Abstract][Full Text] [Related]
14. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
[TBL] [Abstract][Full Text] [Related]
15. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.
Aversa F; Tabilio A; Velardi A; Cunningham I; Terenzi A; Falzetti F; Ruggeri L; Barbabietola G; Aristei C; Latini P; Reisner Y; Martelli MF
N Engl J Med; 1998 Oct; 339(17):1186-93. PubMed ID: 9780338
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: myeloablative, non-myeloablative, and beyond.
Hwang YY; Mohty M; Chim CS
Hematology; 2015 Mar; 20(2):61-71. PubMed ID: 24993587
[TBL] [Abstract][Full Text] [Related]
17. A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia.
Piemontese S; Ciceri F; Labopin M; Bacigalupo A; Huang H; Santarone S; Gorin NC; Koc Y; Wu D; Beelen D; Tischer J; Ehninger G; Arcese W; Nagler A; Mohty M;
Leukemia; 2015 May; 29(5):1069-75. PubMed ID: 25434302
[TBL] [Abstract][Full Text] [Related]
18. Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients.
Gonzalez-Vicent M; Perez A; Abad L; Sevilla J; Ramirez M; Diaz MA
J Pediatr Hematol Oncol; 2010 Apr; 32(3):e85-90. PubMed ID: 20216238
[TBL] [Abstract][Full Text] [Related]
19. Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen.
Kennedy-Nasser AA; Bollard CM; Myers GD; Leung KS; Gottschalk S; Zhang Y; Liu H; Heslop HE; Brenner MK; Krance RA
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1245-52. PubMed ID: 18940679
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study.
Dopfer R; Henze G; Bender-Götze C; Ebell W; Ehninger G; Friedrich W; Gadner H; Klingebiel T; Peters C; Riehm H
Blood; 1991 Nov; 78(10):2780-4. PubMed ID: 1824271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
